Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Tislelizumab in First-Line Fumarate Hydratase Deficient Renal Cell Carcinoma
NCT05877820Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in Fumarate hydratase-deficient renal cell carcinoma (FH-RCC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2023; status: completed.
02
Drugs
lenvatinibtislelizumab
03
Conditions
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC)
Beyond the preview
Go deeper on NCT05877820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877820.